Key Insights

Highlights

Success Rate

81% trial completion

Published Results

19 trials with published results (16%)

Research Maturity

61 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

11.7%

14 terminated out of 120 trials

Success Rate

81.3%

-5.2% vs benchmark

Late-Stage Pipeline

23%

27 trials in Phase 3/4

Results Transparency

31%

19 of 61 completed with results

Key Signals

19 with results81% success14 terminated

Data Visualizations

Phase Distribution

89Total
Not Applicable (31)
P 1 (8)
P 2 (23)
P 3 (21)
P 4 (6)

Trial Status

Completed61
Recruiting17
Terminated14
Unknown9
Withdrawn7
Active Not Recruiting5

Trial Success Rate

81.3%

Benchmark: 86.5%

Based on 61 completed trials

Clinical Trials (120)

Showing 20 of 20 trials
NCT03836300Not ApplicableEnrolling By Invitation

Parent and Infant Inter(X)Action Intervention (PIXI)

NCT05791604Not ApplicableRecruitingPrimary

The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics

NCT03655223Active Not Recruiting

Early Check: Expanded Screening in Newborns

NCT07197034Phase 3Terminated

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

NCT06828861Phase 3Terminated

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

NCT07607730Not ApplicableRecruitingPrimary

Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation

NCT07450664Enrolling By InvitationPrimary

Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

NCT05939453Not ApplicableRecruitingPrimary

Impact of Bright Light Therapy on Prader-Willi Syndrome

NCT07348601Phase 2RecruitingPrimary

A Study of CSTI-500 in Patients With Prader-Willi Syndrome

NCT04257929Phase 2CompletedPrimary

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

NCT03848481Phase 2TerminatedPrimary

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

NCT02529085Not ApplicableCompletedPrimary

PWS European Blood Bank for Infants and Controls From 0 to 48 Months

NCT07219485Phase 3Enrolling By InvitationPrimary

A Study of Pitolisant in Participants With Prader-Willi Syndrome

NCT06366464Phase 3RecruitingPrimary

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06740162Not ApplicableRecruiting

Physical Activity and Community EmPOWERment Project

NCT05945576Recruiting

IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

NCT06772597Phase 2Active Not RecruitingPrimary

A Study of Setmelanotide in Patients With Prader-Willi Syndrome

NCT06573723Recruiting

Institutional Registry of Rare Diseases

NCT04697381Phase 3CompletedPrimary

Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS

NCT06239116Phase 1Recruiting

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Scroll to load more

Research Network

Activity Timeline